ProSight

Company Overview

Snapshot

Founded in May 2017 by Avi Simon and Meir Weksler, ProSight operates with 1–10 employees. The company has raised $6.05M across two funding rounds and has secured a grant from the Israel Innovation Authority in December 2017.

Business overview

ProSight is a medical device startup that develops a real-time ex-vivo biopsy sample scanner for prostate cancer diagnosis. Spun out of the Weizmann Institute of Science, its technology utilizes X-ray fluorescence scanning to identify zinc depletion, a key cancer biomarker, during biopsy procedures. This approach aims to improve tumor detection rates and cancer characterization accuracy, serving the healthcare providers and hospitals within the Health Tech & Life Sciences sector, specifically focusing on diagnostics devices.

Company Intelligence Q&A

What is ProSight's core technology for prostate cancer diagnosis?

ProSight's core technology involves X-ray fluorescence scanning of fresh biopsy samples during the procedure to detect zinc depletion, which is identified as a highly accurate biomarker for prostate cancer. This allows for real-time cancer grading and guidance to suspicious regions.

When was ProSight founded and by whom?

ProSight was founded in May 2017 by Avi Simon and Meir Weksler.

What is the primary market ProSight aims to address?

ProSight aims to become the standard of care in prostate cancer biopsy and diagnosis, targeting a market estimated at $10 billion by improving detection rates and characterization accuracy.

What is the current product stage of ProSight's technology?

ProSight's product is currently in the clinical trial stage, with a prototype developed and successful clinical studies conducted in local medical centers.

Has ProSight secured any non-equity funding?

Yes, ProSight secured a grant from the Israel Innovation Authority in December 2017.